There's lots of anticipation building for the ACC meeting in New Orleans. One of the most closely-watched presentations will detail how torcetrapib failed a trial that experts in the field had widely expected to demonstrate positive efficacy rates. Data on torcetrapib's fatal flaw in raising blood pressure will be forthcoming. Analysts expect that the numbers may shed considerable light on the prospect of other CTEP inhibitors being developed by Roche and Merck. Torcetrapib had demonstrated its effectiveness in raising HDL, an approach that is expected to deliver a key new weapon against heart disease. It had been widely touted as a prospective blockbuster.
- read the report on the upcoming gathering from Newsweek